Avalyn Pharma CFO granted 211,975 stock options
Avalyn Pharma Inc. reported that its Chief Financial Officer, Douglas R. Carlson, received a grant of stock options covering 211,975 shares of Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Avalyn Pharma Inc. reported that its Chief Financial Officer, Douglas R. Carlson, received a grant of stock options covering 211,975 shares of Common Stock. These options have an exercise price of $18.0000 per share and expire on April 28, 2036.
According to the vesting schedule, 25% of the shares vest and become exercisable on September 12, 2025, with the remaining 75% vesting in 36 equal monthly installments, conditioned on his continued service. Following this award, he holds 211,975 derivative securities linked to Avalyn Pharma stock.
Insider Trade Summary
Grant/Award: 211,975 shares
Grant/Award
1 txn
Insider
Carlson Douglas R
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 211,975 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 211,975 contracts (Direct)
Footnotes (1)
- F1. 25% of the shares underlying this option vest and become exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Options granted: 211,975 options
Exercise price: $18.00 per share
Expiration date: April 28, 2036
+4 more
7 metrics
Options granted
211,975 options
Stock Option (Right to Buy) granted to CFO on April 30, 2026
Exercise price
$18.00 per share
Conversion or exercise price of granted options
Expiration date
April 28, 2036
Option term end date
Underlying shares
211,975 shares
Common Stock underlying the option grant
Post-grant derivative holdings
211,975 derivatives
Total derivative securities following transaction
Cliff vesting portion
25% of shares
Vest and become exercisable on September 12, 2025
Remainder vesting
75% over 36 months
Monthly installments after September 12, 2025
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, vesting, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 18.0000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-04-28T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"25% of the shares underlying this option vest and become exercisable on September 12, 2025"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Avalyn Pharma (AVLN) disclose about its CFO’s recent equity award?
Avalyn Pharma disclosed that its CFO, Douglas R. Carlson, received a grant of stock options for 211,975 shares at an exercise price of $18.00 per share, expiring April 28, 2036. The award vests over time, tied to his continued service.
How many Avalyn Pharma (AVLN) stock options were granted to the CFO?
The CFO received stock options covering 211,975 shares of Avalyn Pharma Common Stock. These options are a compensation-related award, not an open-market purchase, and become exercisable gradually based on a specified multi-year vesting schedule tied to his continued employment.
What is the exercise price and term of the Avalyn Pharma (AVLN) CFO stock options?
The options have an exercise price of $18.00 per share and expire on April 28, 2036. This gives the CFO the right to buy Avalyn Pharma Common Stock at that price if and when the options vest and he chooses to exercise.
How do the Avalyn Pharma (AVLN) CFO stock options vest over time?
Twenty-five percent of the shares underlying the option vest and become exercisable on September 12, 2025. The remaining 75% vest in 36 equal monthly installments thereafter, provided the CFO continues to serve the company on each monthly vesting date.
Are the Avalyn Pharma (AVLN) CFO’s stock options an open-market purchase or a grant?
The transaction is a grant of stock options as compensation, coded as a grant, award, or other acquisition. It is not an open-market share purchase, and no shares were sold; the CFO received the right to buy shares in the future at a fixed price.
AI-generated analysis. How Rhea-AI works. Not financial advice.
